RT Journal Article
SR Electronic
T1 Spatial and temporal regularization to estimate COVID-19 Reproduction Number <em>R</em>(<em>t</em>): Promoting piecewise smoothness via convex optimization
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.10.20127365
DO 10.1101/2020.06.10.20127365
A1 Patrice Abry
A1 Nelly Pustelnik
A1 Stéphane Roux
A1 Pablo Jensen
A1 Patrick Flandrin
A1 Rémi Gribonval
A1 Charles-Gérard Lucas
A1 Eric Guichard
A1 Pierre Borgnat
A1 Nicolas Garnier
A1 Benjamin Audit
YR 2020
UL http://medrxiv.org/content/early/2020/06/12/2020.06.10.20127365.abstract
AB Among the different indicators that quantify the spread of an epidemic, such as the on-going COVID-19, stands first the reproduction number which measures how many people can be contaminated by an infected person. In order to permit the monitoring of the evolution of this number, a new estimation procedure is proposed here, assuming a well-accepted model for current incidence data, based on past observations. The novelty of the proposed approach is twofold: 1) the estimation of the reproduction number is achieved by convex optimization within a proximal-based inverse problem formulation, with constraints aimed at promoting piecewise smoothness; 2) the approach is developed in a multivariate setting, allowing for the simultaneous handling of multiple time series attached to different geographical regions, together with a spatial (graph-based) regularization of their evolutions in time. The effective-ness of the approach is first supported by simulations, and two main applications to real COVID-19 data are then discussed. The first one refers to the comparative evolution of the reproduction number for a number of countries, while the second one focuses on French counties and their joint analysis, leading to dynamic maps revealing the temporal co-evolution of their reproduction numbers.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNO specific funding was received for this workAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No approval necessary; only public and anonymous data were used.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data processed in this paper is publicly available in repositories. https://raw.githubusercontent.com/CSSEGISandData/COVID-19/master/csse_covid_19_time_series/ https://www.ecdc.europa.eu/sites/default/files/documents/COVID-19-geographic-disbtribution-worldwide.xlsx https://coronavirus.jhu.edu/ https://www.ecdc.europa.eu/ https://www.santepubliquefrance.fr/